Nutriband Inc. (NTRB)
NASDAQ: NTRB · IEX Real-Time Price · USD
5.89
-0.10 (-1.67%)
Jul 2, 2024, 4:30 PM EDT - Market closed
Company Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.
The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Gareth Sheridan |
Contact Details
Address: 121 S. Orange Ave., Suite 1500 Orlando, Florida 32801 United States | |
| Phone | 407 377-6695 |
| Website | nutriband.com |
Stock Details
| Ticker Symbol | NTRB |
| Exchange | NASDAQ |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0001676047 |
| CUSIP Number | 67092M208 |
| ISIN Number | US67092M2089 |
| Employer ID | 81-1118176 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Gareth Sheridan | Founder, Chief Executive Officer and Director |
| Serguei Melnik | Founder, President, Company Secretary and Executive Chairman of the Board |
| Gerald Goodman | Chief Financial Officer and Chief Accounting Officer |
| Dr. Alan Smith Ph.D. | Chief Operating Officer and President of 4P Therapeutics |
| Patrick Ryan | Chief Technical Officer |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer |
| Tyler Overk | President of Active Intelligence |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 3, 2024 | 8-K/A | [Amend] Current report |
| May 31, 2024 | 10-Q | Quarterly Report |
| May 21, 2024 | 8-K | Current Report |
| May 17, 2024 | 8-K | Current Report |
| May 1, 2024 | 10-K | Annual Report |
| May 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 23, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |